Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Account Payables
Amounts the company owes suppliers for goods and services received.
Monopar Therapeutics Inc.NASDAQ: MNPR
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 64.7% from a year ago
Account payables stood at $2.46M at the end of Q1 FY2026, up 64.7% from a year earlier and down 10.1% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.
Context
- Account payables amounted to 1.8% of total assets at the end of Q1 FY2026, down 0.9 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +64.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.74M USD
- Year-over-year change
- +21.3%
- 4-year CAGR
- +14.7%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.74M | +21.3% |
| FY2024 | 2024-12-31 | 2.25M | +28.3% |
| FY2023 | 2023-12-31 | 1.76M | -43.8% |
| FY2022 | 2022-12-31 | 3.13M | +98.0% |
| FY2021 | 2021-12-31 | 1.58M | — |
Account Payables vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +64.7% is the 3rd highest of 11, against a peer median of -29.6%.
- Account payables amounts to 1.8% of total assets for MNPR, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $131.86M USD | +10004.4% | -17.6% | 11.2% | |
| Dec 2025 | €15.04M EUR | +89.8% | +3.3% | 24.0% | |
| Jun 2026 | $12.65M USD | -31.8% | +2.4% | 1.7% | |
| Jun 2026 | $8.51M USD | +10.4% | — | 21.2% | |
| Mar 2026 | $5.97M USD | -46.3% | +14.3% | 0.9% | |
| Mar 2026 | $5.3M USD | -66.0% | -9.4% | 1.8% | |
| Sep 2026 | $4.46M USD | -27.4% | +11.6% | 0.9% | |
| Mar 2026 | $4.29M USD | -35.2% | -0.8% | 2.0% | |
| Mar 2026 | $3.85M USD | -2.1% | -15.3% | 2.2% | |
| Mar 2026 | $2.46M USD | +64.7% | -4.4% | 1.8% | |
| Mar 2026 | $906K USD | -42.5% | -22.3% | 0.4% | |
| Peer median (excluding MNPR) | — | -29.6% | -0.8% | 1.9% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.